EGL-003

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameEGL-003
Drug Alias NameEGL-003
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > T cell engagers
Mechanisms of ActionT lymphocyte replacementsInterleukin-2 agonists
TargetsInterleukin-2
Therapy Area/IndicationsAutoimmune DiseasesDermatitis, AtopicNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEgle Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesEgle Therapeutics
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesDermatitis, AtopicNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A